Competitor Analysis: Inhibitory and Stimulatory Immunomodulators in Immuno-Oncology

MarketResearchReports.Biz presents this most up-to-date research on “Competitor Analysis: Inhibitory and Stimulatory Immunomodulators in Immuno-Oncology”


Competitor Analysis: Inhibitory and Stimulatory Immunomodulators in Immuno-Oncology

This product consists of four reports in pdf format describing the competitive field of new molecular entities directed against inibitory as well stimulatory immune checkpoints on T-cells, antigen presenting cells (APCs)/dendritic cells or tumor cells and against immunosuppressive factors in the tumor microencironment, including Treg cells, tumor-associated macrophages (TAM), myeloid derived suppressor cells (MDSC).

Purchase of this product includes a 6-month online access to the data of the reports and any updates since the publication date as well as the clinical and preclinical combination studies. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Each of the four reports can be obtained individually, but the package of the four reports provides a 40% discount on the regular prices:

Competitor Analysis: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2016

Competitor Analysis: Inhibitors of Negative Immune Checkpoints CTLA-4, LAG-3, TIM-3 & Others

Competitor Analysis: Activators of Immune Checkpoints CD40, GITR, OX40, 4-1BB, CD27 & ICOS

Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-B/R, CXCR4, CSF-1R, CD47-SIRPa, Adenosine, STING & Others

Targets of Immunomodulators are inhibitory as well as stimulatory immune checkpoints and from the tumor microenvironment:

Negative Immune Checkpoints:

PD-1(programmed cell death 1

PD-L1(programmed cell death ligand 1 (PD-L1)

(Cytotoxic T-Lymphocyte-Associated Protein-4; CD152)

(Lymphocyte Activation Gene 3; CD223)

(T-cell Immunoglobulin domain and Mucin domain 3; HAVCR2)

(V-region Ig-containing Suppressor of T-cell Activation) Receptor

(Carcino-Embryonic Antigen Cell Adhesion Molecule 1)

BTLA (B- and T-Lymphocyte Attenuator)

GARP (Glycoprotein A Repetitions Predominant)

TIGIT(T-cell Immunoreceptor with Ig and ITIM domains)



Request Sample Copy of This Report at:

Stimulatory Immune Checkpoints:


GITR(Glucocorticoid-Induced Tumor Necrosis Factor Receptor; TNFSFR18)

OX40(CD134; TNFSFR4)

4-1BB(CD137; TNFSFR9)


ICOS(Inducible Co-Stimulator)

Immunosuppressive tumor microenvironment:

IDO (Indoleamine 2,3-dioxygenase

TDO ( Tryptophan 2,3 dioxygenase)

TGF-B/R ( Transforming Growth Factor beta/Receptor)

CXCR4 (Chemokine Receptor Type 4)

CSF-1R ( Colony Stimulating Factor-1 Receptor)

CD47 SIRPa (Signal Regulatory Protein Alpha)

Adenosine Pathway: Adenosine 2A Receptor (A2AR), CD73, CD39 & adenosine

STING (STimulator of INterferon Genes) Receptor

Others ( e.g. arginase)

About us is the most comprehensive collection of market research reports.

MarketResearchReports.Biz services are specially designed to save time and money for our clients.

We are a one stop solution for all your research needs, our main offerings are syndicated research

reports, custom research, subscription access and consulting services. We serve all sizes and types

of companies spanning across various industries.

Browse Latest Industry Press Release at:


State Tower

90 State Street, Suite 700

Albany, NY 12207

United States

Tel: +1-518-621-2074



Follow us on LinkedIn:

Designed by
Powered by